{"transactions":[{"id":742257,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-06-11T20:25:35.000Z","date":"2026-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":93750,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the \"Merger Agreement\"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni (\"Parent\"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Company Common Stock\"), for a price per share of $27.00 (the \"Merger Consideration\"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a \"Company RSU Award\"), that was outstanding immediately prior to the Effective Time, became fully vested, and was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the Merger Consideration multiplied by (B) the number of shares of Company Common Stock subject to such Company RSU immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on April 16, 2026, subject to continued service through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on April 16, 2026, subject to continued service through each vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":93750},"source":{"system":"sec-edgar","filing":"0001815308-26-000006","document":"form4-06112026_080631.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000181530826000006/form4-06112026_080631.xml","form_type":"4"}},{"id":742256,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-06-11T20:25:35.000Z","date":"2026-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":55000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the \"Merger Agreement\"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni (\"Parent\"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Company Common Stock\"), for a price per share of $27.00 (the \"Merger Consideration\"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a \"Company RSU Award\"), that was outstanding immediately prior to the Effective Time, became fully vested, and was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the Merger Consideration multiplied by (B) the number of shares of Company Common Stock subject to such Company RSU immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"3/16th of the total number of shares underlying the RSUs shall vest on November 21, 2025 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"3/16th of the total number of shares underlying the RSUs shall vest on November 21, 2025 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate"}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001815308-26-000006","document":"form4-06112026_080631.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000181530826000006/form4-06112026_080631.xml","form_type":"4"}},{"id":742255,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:25:35.000Z","date":"2026-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the \"Merger Agreement\"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni (\"Parent\"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Company Common Stock\"), for a price per share of $27.00 (the \"Merger Consideration\"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each option to purchase shares of Company Common Stock (\"Company Option\") that was outstanding and unexercised immediately prior to the effective time of the Merger (the \"Effective Time\") and had a per share exercise price that was less than the Merger Consideration became fully vested, was cancelled and converted into the right of the holder thereof to receive a cash payment (without interest) equal to the product of (A) the excess of (x) the Merger Consideration over (y) the per share exercise price of such Company Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time. Each Company Option that was outstanding and unexercised immediately prior to the Effective Time and had a per share exercise price that is equal to or greater than the Merger Consideration was automatically cancelled for no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests over a 4 year period: 25% on September 9, 2025, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date."}],"balance_after":0,"derivative":{"exercise_price":11.87,"expiration_date":"2034-09-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001815308-26-000006","document":"form4-06112026_080631.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000181530826000006/form4-06112026_080631.xml","form_type":"4"}},{"id":742254,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-11T20:25:35.000Z","date":"2026-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":21661,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026 (the \"Merger Agreement\"), by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\"), Chiesi Farmaceutici S.p.A., an Italian societa per azioni (\"Parent\"), and Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Company Common Stock\"), for a price per share of $27.00 (the \"Merger Consideration\"), without interest, less any applicable tax withholding. Effective as of June 11, 2026, Merger Sub merged with and into the Company with the Company surviving the Merger as a wholly owned subsidiary of the Parent (the \"Merger\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001815308-26-000006","document":"form4-06112026_080631.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000181530826000006/form4-06112026_080631.xml","form_type":"4"}},{"id":764621,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-05-26T23:32:59.000Z","date":"2026-05-21","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"3/16th of the total number of shares underlying the RSUs vested on November 21, 2025 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"3/16th of the total number of shares underlying the RSUs vested on November 21, 2025 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate."}],"balance_after":55000,"derivative":{"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001815308-26-000004","document":"form4-05262026_110551.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000181530826000004/form4-05262026_110551.xml","form_type":"4"}},{"id":764620,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-26T23:32:59.000Z","date":"2026-05-22","kind":"sale","planned":false,"acquired":false,"shares":1489,"price":26.7844,"value":39881.9716,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":21661,"source":{"system":"sec-edgar","filing":"0001815308-26-000004","document":"form4-05262026_110551.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000181530826000004/form4-05262026_110551.xml","form_type":"4"}},{"id":764619,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-26T23:32:59.000Z","date":"2026-05-21","kind":"exercise","planned":false,"acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":23150,"source":{"system":"sec-edgar","filing":"0001815308-26-000004","document":"form4-05262026_110551.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000181530826000004/form4-05262026_110551.xml","form_type":"4"}},{"id":804739,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-04-20T23:40:54.000Z","date":"2026-04-16","kind":"exercise","planned":false,"acquired":false,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on April 16, 2026, subject to continued service through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on April 16, 2026, subject to continued service through each vesting date."}],"balance_after":93750,"derivative":{"underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001815308-26-000003","document":"form4-04202026_110449.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000181530826000003/form4-04202026_110449.xml","form_type":"4"}},{"id":804738,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-20T23:40:54.000Z","date":"2026-04-17","kind":"sale","planned":false,"acquired":false,"shares":1862,"price":20.2163,"value":37642.7506,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":18150,"source":{"system":"sec-edgar","filing":"0001815308-26-000003","document":"form4-04202026_110449.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000181530826000003/form4-04202026_110449.xml","form_type":"4"}},{"id":804737,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-20T23:40:54.000Z","date":"2026-04-16","kind":"exercise","planned":false,"acquired":true,"shares":6250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":20012,"source":{"system":"sec-edgar","filing":"0001815308-26-000003","document":"form4-04202026_110449.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000181530826000003/form4-04202026_110449.xml","form_type":"4"}},{"id":886297,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-25T00:42:06.000Z","date":"2026-02-21","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"3/16th of the total number of shares underlying the RSUs vested on November 21, 2025 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"3/16th of the total number of shares underlying the RSUs vested on November 21, 2025 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate."}],"balance_after":60000,"derivative":{"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001815308-26-000002","document":"form4-02252026_120203.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000181530826000002/form4-02252026_120203.xml","form_type":"4"}},{"id":886296,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-25T00:42:06.000Z","date":"2026-02-23","kind":"sale","planned":false,"acquired":false,"shares":1767,"price":15.5668,"value":27506.5356,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.5253 to $15.56698 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":13762,"source":{"system":"sec-edgar","filing":"0001815308-26-000002","document":"form4-02252026_120203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000181530826000002/form4-02252026_120203.xml","form_type":"4"}},{"id":886295,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-25T00:42:06.000Z","date":"2026-02-21","kind":"exercise","planned":false,"acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":15529,"source":{"system":"sec-edgar","filing":"0001815308-26-000002","document":"form4-02252026_120203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000181530826000002/form4-02252026_120203.xml","form_type":"4"}},{"id":934684,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-01-21T21:10:39.000Z","date":"2026-01-16","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 22, 2026, for so long as grantee's Service (as defined in the Plan) does not terminate."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 22, 2026, for so long as grantee's Service (as defined in the Plan) does not terminate."}],"balance_after":100000,"derivative":{"underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001815308-26-000001","document":"form4-01212026_090135.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000181530826000001/form4-01212026_090135.xml","form_type":"4"}},{"id":987925,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-11-26T23:50:29.000Z","date":"2025-11-21","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"3/16th of the total number of shares underlying the RSUs vested on November 21, 2024 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"3/16th of the total number of shares underlying the RSUs vested on November 21, 2024 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate."}],"balance_after":65000,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001815308-25-000004","document":"form4-11262025_111126.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000181530825000004/form4-11262025_111126.xml","form_type":"4"}},{"id":987924,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-11-26T23:50:29.000Z","date":"2025-11-24","kind":"sale","planned":false,"acquired":false,"shares":4471,"price":13.451,"value":60139.421,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":10529,"source":{"system":"sec-edgar","filing":"0001815308-25-000004","document":"form4-11262025_111126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000181530825000004/form4-11262025_111126.xml","form_type":"4"}},{"id":987923,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-11-26T23:50:29.000Z","date":"2025-11-21","kind":"exercise","planned":false,"acquired":true,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001815308-25-000004","document":"form4-11262025_111126.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000181530825000004/form4-11262025_111126.xml","form_type":"4"}},{"id":1247622,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-02-26T01:35:13.000Z","date":"2025-02-21","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"3/16th of the total number of shares underlying the RSUs shall vest on November 21, 2024 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"3/16th of the total number of shares underlying the RSUs shall vest on November 21, 2024 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate."}],"balance_after":80000,"derivative":{"underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001415889-25-005611","document":"form4-02262025_010210.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000141588925005611/form4-02262025_010210.xml","form_type":"4"}},{"id":1410264,"issuer":{"id":39180,"kind":"organization","name":"KalVista Pharmaceuticals, Inc.","symbol":"KALV"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-09-11T20:34:04.000Z","date":"2024-09-09","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a 4 year period: 25% on September 9, 2025, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The option vests over a 4 year period: 25% on September 9, 2025, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date."}],"balance_after":100000,"derivative":{"exercise_price":11.87,"underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-24-023216","document":"form4-09112024_080900.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000141588924023216/form4-09112024_080900.xml","form_type":"4"}},{"id":1659723,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-05T11:01:51.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":43225,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty five percent (25%) of the stock options vest on February 1, 2025, the one-year anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates."}],"balance_after":43225,"derivative":{"exercise_price":4.5,"expiration_date":"2034-02-01","underlying":"Common Stock","underlying_shares":43225},"source":{"system":"sec-edgar","filing":"0001140361-24-005499","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000114036124005499/form4.xml","form_type":"4"}},{"id":1868163,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-05T21:25:16.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":75484,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the option shares on May 15, 2024 with the remainder vesting in 36 equal monthly installments at the end of each month thereafter, subject to the Reporting Person continuing to provide services to the Issuer through the applicable vesting dates, and provided that in the event there is a change in control of the Issuer, followed by a subsequent termination of the Reporting Person's employment without cause (or a material diminishment of his role) within 12 months of the change of control, any unvested options granted will immediately vest."}],"balance_after":75484,"derivative":{"exercise_price":10,"expiration_date":"2033-06-01","underlying":"Common Stock","underlying_shares":75484},"source":{"system":"sec-edgar","filing":"0001140361-23-028420","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000114036123028420/form4.xml","form_type":"4"}},{"id":2248187,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2022-06-02T23:14:01.000Z","date":"2022-05-31","kind":"grant","acquired":true,"shares":9960,"price":1.09,"value":10856.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Gemini Therapeutics, Inc. 2021 Employee Stock Purchase Plan (\"ESPP\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the terms of the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on May 31, 2022."}],"balance_after":17615,"source":{"system":"sec-edgar","filing":"0001209191-22-033719","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000120919122033719/doc4.xml","form_type":"4"}},{"id":2435294,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Restricted Stock Units","published_at":"2022-01-14T14:01:21.000Z","date":"2022-01-13","kind":"grant","acquired":true,"shares":280876,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the right to receive one share of Gemini Therapeutics, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These Restricted Stock Units shall vest on the one (1)-year anniversary of the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These Restricted Stock Units shall vest on the one (1)-year anniversary of the date of grant."}],"balance_after":280876,"derivative":{"underlying":"Common Stock","underlying_shares":280876},"source":{"system":"sec-edgar","filing":"0001209191-22-003268","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000120919122003268/doc4.xml","form_type":"4"}},{"id":2538450,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-10-20T21:49:59.000Z","date":"2021-10-18","kind":"grant","acquired":true,"shares":90720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents the right to receive one share of Gemini Therapeutics, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Thirty-three percent (33%) of the Restricted Stock Units shall vest upon the achievement of a clinical milestone, and the remaining sixty-seven percent (67%) of the Restricted Stock Units shall vest on the one (1)-year anniversary of the achievement of this clinical milestone."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Thirty-three percent (33%) of the Restricted Stock Units shall vest upon the achievement of a clinical milestone, and the remaining sixty-seven percent (67%) of the Restricted Stock Units shall vest on the one (1)-year anniversary of the achievement of this clinical milestone."}],"balance_after":90720,"derivative":{"underlying":"Common Stock","underlying_shares":90720},"source":{"system":"sec-edgar","filing":"0000899243-21-040808","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000089924321040808/doc4.xml","form_type":"4"}},{"id":2708976,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-05-18T20:45:22.000Z","date":"2021-05-14","kind":"purchase","acquired":true,"shares":7655,"price":9.462,"value":72431.61,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.30 to $9.50. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request."}],"balance_after":7655,"source":{"system":"sec-edgar","filing":"0000899243-21-019763","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000089924321019763/doc4.xml","form_type":"4"}},{"id":2749858,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-14T20:06:30.000Z","date":"2021-04-12","kind":"grant","acquired":true,"shares":377734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable over a period of four years from the Vesting Start Date, April 12, 2021, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company."}],"balance_after":377734,"derivative":{"exercise_price":12.59,"expiration_date":"2031-04-11","underlying":"Common Stock","underlying_shares":377734},"source":{"system":"sec-edgar","filing":"0001213900-21-021524","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815308/000121390021021524/ownership.xml","form_type":"4"}},{"id":2978777,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-17T15:42:01.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":9500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9500},"source":{"system":"sec-edgar","filing":"0001104659-20-126319","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126319/a4.xml","form_type":"4"}},{"id":2978776,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":39434,"kind":"person","name":"Piekos Brian","position":1,"cik":"0001815308","reported_name":"Piekos Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-11-17T15:42:01.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":31538,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. (\"Parent\"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of November 16, 2020 (the \"Effective Time\"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a \"Share\") was cancelled and converted into the right to receive $13.75 in cash (the \"Merger Consideration\") without interest and subject to applicable withholding taxes."},{"field":"shares","element":"transactionShares","label":"F2","text":"A portion of this amount consists of unvested restricted stock units (\"RSUs\"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. (\"Parent\"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of November 16, 2020 (the \"Effective Time\"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a \"Share\") was cancelled and converted into the right to receive $13.75 in cash (the \"Merger Consideration\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"A portion of this amount consists of unvested restricted stock units (\"RSUs\"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-126319","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126319/a4.xml","form_type":"4"}}]}